This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Obesity is linked to an increased risk of atrialfibrillation (AF) via increased oxidative stress. Here, we studied NOX2-mediated ROS production in obesity-mediated AF using Nox2-knockout mice and mature human induced pluripotent stem cell–derived atrial cardiomyocytes (hiPSC-aCMs).
BackgroundObesity is an important risk factor for atrialfibrillation (AF) development and progression. Furthermore, obesity reduces health-related quality of life (HRQoL), an essential indicator for treatment efficacy of AF ablation. Heart rhythm was systematically monitored during follow-up.
This randomized clinical trial investigates which strategy is more effective in patients with atrialfibrillation and obesity: dual or single direct-current cardioversion.
Obesity is a multifaceted disease that is directly and indirectly implicated in atherosclerotic cardiovascular disease (CVD), heart failure (HF), atrialfibrillation (AF), and multiple CVD risk factors, including dyslipidemia, hypertension, type 2 diabetes mellitus (DM), and sleep disorders.
The goal of the Dual vs. Single DCCV trial was to determine the efficacy and safety of dual direct-current cardioversion (DCCV) compared with single DCCV in patients with obesity and atrialfibrillation (AF) undergoing elective electrical cardioversion.
Background Efforts to maintain sinus rhythm in patients with persistent atrialfibrillation (PsAF) remain challenging, with suboptimal long-term outcomes. Twelve (50%) patients were obese. Methods All patients undergoing convergent PsAF ablation at our centre were retrospectively analysed. All were longstanding persistent.
Catheter Ablation for AtrialFibrillation (AFib) in heart failure is now a class I indication for patients with heart failure. Evidence supports the relationship between obesity and the incidence and recurrence of Afib.
Atrialfibrillation (AF) is the most prevalent arrhythmia in clinical practice, and obesity serves as a significant risk factor for its development. The underlying mechanisms of obesity-related AF remain intri.
BackgroundAtrial fibrillation (AF) is a common cardiac arrhythmia that is associated with obesity and obstructive sleep apnea syndrome (OSA). Through mediating MR analysis, it was found that OSA played a certain role in the causal relationship between obesity and AF, with about 6.4%
Cancer, atrialfibrillation (AF) and coronary artery disease share some common factors and interact with each other, such as obesity, aging, diabetes, and inflammation, but the potential specific mechanism is still unclear. Meanwhile, the risk of suffering from cardiovascular disease (CVD) has been increasing with ageing.
ABSTRACTAtrial fibrillation (AF) is the most common cardiac arrhythmia. Obesity significantly increases AF risk, both directly and indirectly, through related conditions, like hypertension, diabetes, and heart failure. However, studies on how obesity affects pharmacologic or interventional AF treatments are limited.
BackgroundThe economic burden of nonvalvular atrialfibrillation (NVAF) is substantial. Many patients with NVAF are obese and manage other health conditions requiring multiple medications. Journal of the American Heart Association, Ahead of Print.
million Americans have atrialfibrillation. Atrialfibrillation, a rapid, irregular heart beat that can lead to stroke or sudden death, is three times more common than previously thought, affecting nearly 5 percent of the population, or 10.5 tim.hodson Wed, 09/11/2024 - 15:40 Sept. million U.S. million U.S.
BackgroundMultimorbidity is common among patients with atrialfibrillation (AF) and is associated with worse outcomes. Multimorbidity was defined as 2 comorbidities (heart failure, hypertension, diabetes, coronary heart disease, kidney dysfunction, moderate or severe mitral valve regurgitation, or obesity).
Following pulmonary vein isolation (PVI), about a third of patients have a very late recurrence (VLR) of atrialfibrillation (AF), defined as an AF recurrence after being free of AF for the first year following ablation. Additional data are needed to understand which patients remain at risk for VLR.
1 Atrialfibrillation (AF) is the most common cardiac arrhythmia, affecting more than 6 million individuals in the United States.2 2 As noted elsewhere,3 DM and AF affect a population that shares concomitant conditions such as obesity, hypertension and even heart failure (HF). of the population.1
Aging is a risk factor for atrialfibrillation (AF). In 19-month-old mice, increases in AF inducibility are associated with an increase in the levels of the fat mass and obesity-associated (Fto) protein, and a reduction of N6-Methyladenosine (m6A) modification in atrial tissue.
Objective Atrialfibrillation (AF) is a condition that occurs in the presence of comorbidities. years), obese and hypertensive cluster carrying an intermediate risk (5.9%) of incident AF. With the accumulation of comorbidities (multimorbidity), some combinations may more often occur together than others.
Atrialfibrillation (AF), the most prevalent cardiac arrhythmia, is closely linked to metabolic dysfunctions, including obesity, diabetes, and dyslipidemia. These lead to pathological changes in myocardial metabolism and mitochondrial energy metabolism, thereby aggravating AF's incidence and severity.
Heart failure with preserved ejection fraction (HFpEF) and atrialfibrillation (AF) are comorbid conditions that are increasingly prevalent and have a high socioeconomic burden. This article discusses their shared pathophysiology, focusing on the triad of hypertension, obesity, and aging.We
We previously reported that first-pass pulmonary vein (PV) isolation (FPI) is related to the PV isolation (PVI) durability in ablation index (AI) guided catheter ablation for atrialfibrillation (AF) (J Cardiovasc Electrophysiol 2023). However, the impact of obesity on FPI has been scarcely reported.
A projected rise in heart disease and stroke – along with several key risk factors, including high blood pressure and obesity – is likely to triple related costs to $1.8 A projected rise in heart disease and stroke – along with several key risk factors, including high blood pressure and obesity – is likely to triple related costs to $1.8
AtrialFibrillation (AF) is a heart arrhythmia with influences from lifestyle risk factors like alcohol use and obesity. As such, patient lifestyles have a prominent role in managing AF.
It incorporates age, body mass index (BMI), and atrialfibrillation to aid in the diagnosis of HFpEF. The newly developed HFpEF-ABA score model estimates the probability of HFpEF in individual patients based on three simple clinical variables: age, BMI, and atrialfibrillation.
They have a greater prevalence of obesity, dyslipidemia, metabolic syndrome and diabetes mellitus. Higher risk of myocardial infarction, heart failure and atrialfibrillation was noted in spinal cord injury survivors compared to controls. Survivors with severe disability had the highest risk. Am J Phys Med Rehabil. 2023.12.010.
to 26.8%) and obesity (43.1% to 6.4%), atrialfibrillation (1.7% We projected through 2050, overall and by age and race and ethnicity, accounting for changes in disease prevalence and demographics.RESULTS:We estimate that among adults, prevalence of hypertension will increase from 51.2% in 2020 to 61.0% Diabetes (16.3%
Getty Images milla1cf Fri, 12/08/2023 - 08:17 December 8, 2023 — The American College of Cardiology (ACC) and the American Heart Association (AHA), along with several other leading medical associations, have issued a new guideline for preventing and optimally managing atrialfibrillation (AFib).
Atrialfibrillation (AF) is responsible for significant patient morbidity, and obesity is a major contributor to AF incidence and symptom burden. This randomised study set out to examine if smartphone-based app technology could increase weight loss in a patient population with obesity and AF.
Abstract Background Obesity is associated with an increased risk of developing recurrent atrialfibrillation (AF) after catheter ablation (CA). However, the current data on weight loss interventions show inconsistent results in preventing the recurrence of AF after CA.
For ICM patients who are at the highest risk of AF detection (those with left atrial enlargement, heart failure , obesity, or prolonged QRS), the cost per QALY is reduced even further to $22,016. “In Additionally, patients with ICMs were estimated to experience a gain of 0.17 of $150,000 per QALY.
vs. 43.6%, p=0.007), and were less often obese (34.0% Circulation, Volume 150, Issue Suppl_1 , Page A4141940-A4141940, November 12, 2024. Compared to the no prior SSE group, those with prior SSE were less symptomatic (61.3% vs. 72.8%, p<0.001), had higher rates of diabetes (49.1% vs. 42.4%, p=0.03) and dyslipidemia (51.9%
million Americans have atrialfibrillation. Atrialfibrillation, a rapid, irregular heart beat that can lead to stroke or sudden death, is three times more common than previously thought, affecting nearly 5 percent of the population, or 10.5 tim.hodson Wed, 09/11/2024 - 15:40 Sept. million U.S. million U.S.
Obesity, diabetes, and the metabolic syndrome are risk factors for atrialfibrillation (AF). AF is also associated with cardiomyocyte metabolic stress. We hypothesized that antidiabetic medications (ADMs) may affect AF incidence.
Objectives In dyspneic patients with atrialfibrillation (AF) or obesity, the diagnostic performance of NT-proBNP for acute heart failure is reduced. The diagnostic performance of ERFE is impaired in patients with AF but not patients with obesity.
September is National AtrialFibrillation (AFib) Awareness Month, a time dedicated to raising awareness about one of the most common yet often misunderstood heart conditions. Understanding AtrialFibrillationAtrialFibrillation is characterized by an irregular and often rapid heart rhythm that can lead to poor blood flow.
Introduction:Identification of atrialfibrillation (AF) in patients with stroke is critical for secondary stroke prevention with guideline-recommended oral anticoagulation (OAC). In the patients at highest risk of AF detection (left atrial enlargement, heart failure, obesity, or prolonged QRS), the cost/QALY was $22,016.Conclusions:ICMs
Obesity is associated with reduced catheter ablation-induced scar formation on late-gadolinium enhancement MRI. Abstract Introduction Obesity is implicated in adverse atrial remodeling and worse outcomes in patients with atrialfibrillation. Comorbidities were more prevalent in obese patients.
September is National AtrialFibrillation (AFib) Awareness Month, a time dedicated to raising awareness about one of the most common yet often misunderstood heart conditions. Understanding AtrialFibrillationAtrialFibrillation is characterized by an irregular and often rapid heart rhythm that can lead to poor blood flow.
Heart Disease in 2050 – The AHA warned of massive heart disease increases by 2050, spanning CVD (+60%), diabetes (+100%), obesity (+70%), hypertension (+44%), heart failure (+66%), and stroke (+100%). AFib Wakeup Call – A JACC study suggested that atrialfibrillation is far more prevalent than many thought.
Optimal NT-proBNP cut points for HFpEF rule out (optimizing sensitivity) and rule in (optimizing specificity) were derived and tested, stratified by obesity and atrialfibrillation. In our study, NT-proBNP provided little value in those with AF and dyspnea because the presence of AF is by itself a robust biomarker of HFpEF.
Black History Month is a poignant backdrop to the alarming rise in obesity and type 2 diabetes, particularly among those of marginalized populations. This troubling trend has cemented the 100-year reign of cardiovascular diseases (CVD) as the #1 killer in America.
Atrialfibrillation, a common consequence of high blood pressure in Western populations, is almost unheard of in the Tsimane Tribe. For other significant risk factors, the trend is also the same, with almost nonexistent rates of obesity, abnormal glycemic control and very low rates of smoking 14. Am J Phys Anthropol.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content